ArticleSurgical case reports2026
A Case of Pathological Complete Response after "Conversion Surgery" for Initially Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntrahepatic cholangiocarcinoma (iCCA) is the second most common liver cancer and has a poor prognosis. Given the recent advancements in drug therapy, the topic of so-called "conversion surgery" in biliary tract cancer, including iCCA, is evolving; however, only a few cases have been reported. CASE PRESENTATION: A 50-year-old female was referred to our hospital for a liver tumor identified on abdominal ultrasonography. She was diagnosed with iCCA based on tumor biopsy. Due to extensive vascular and bile duct invasion, iCCA was initially considered unresectable. After 8 cycles of gemcitabine, cisplatin plus S-1 (GCS) therapy, CT revealed a partial response. Considering that microsatellite instability-high (MSI-H) was detected, we switched the regimen from GCS to pembrolizumab. However, after 1 cycle of pembrolizumab therapy, immune checkpoint inhibitor (ICI)-induced hepatitis was suspected; therefore, pembrolizumab therapy was suspended. GCS therapy was restarted, and after another 3 cycles, the iCCA was deemed resectable; therefore, conversion surgery was performed. Postoperative histopathological examination revealed a pathological complete response (pCR), and the patient remained alive more than 5 years postoperatively without recurrence or metastasis.
conclusionsWe experienced a case of pCR induced by GCS chemotherapy and pembrolizumab monotherapy. Although the direct contribution of pembrolizumab remains unclear, a possible synergistic effect with GCS chemotherapy was suggested, particularly in MSI-H tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.